Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home-Based Daratumumab Administration for Multiple Myeloma
NCT05511428Phase 4Completed
- Sponsor
- Thomas Jefferson University
- Start
- Nov 2022
- Primary completion
- May 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of Darzalex Faspro in multiple myeloma (MM), sponsored by Thomas Jefferson University. Started Nov 2022; status: completed.
02
Drugs
Darzalex Faspro
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05511428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511428.